Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Imatinib (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 22 Oct 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017, as reported by ClinicalTrials.gov.
- 09 Oct 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.